Dale Cowley

Dr. Dale Cowley

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2025 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
LGLesley R. Golden
Lesley R. Golden
DSDahlia S. Siano
Dahlia S. Siano
ISIsaiah O. Stephens
Isaiah O. Stephens
SMSteven M. MacLean
Steven M. MacLean
KSKai Saito
Kai Saito
LJLance A. Johnson
Lance A. Johnson
Compared to individuals carrying two copies of the ε4 allele of apolipoprotein E (APOE), ε2 homozygotes have an approximate 99% reduction in late-onset Alzheimer’s disease (AD) risk. Here we develop a knock-in model that allows for an inducible ‘switch’ between risk and protective alleles (APOE4s2). Gene expression and proteomic analyses confirm that APOE4s2 mice synthesize E4 at baseline and E2 after tamoxifen administration. A whole-body allelic switch results in a metabolic profile resembling E2/E2 humans and drives AD-relevant alterations in the lipidome and single-cell transcriptome, particularly in astrocytes. Finally, when crossed to the 5xFAD background, astrocyte-specific E4 to E2 switching improves cognition, decreases amyloid pathology, lowers gliosis and reduces plaque-associated apolipoprotein E. Together, these data show that a short-term transition from APOE4 to APOE2 can broadly affect the cerebral transcriptome and lipidome, and that astrocyte-specific APOE replacement may be a viable strategy for future gene editing approaches to simultaneously reduce multiple AD-associated pathologies.

22 September 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
LSLu Sun
Lu Sun
HFHui Feng
Hui Feng
IMIchiro Misumi
Ichiro Misumi
TSTakayoshi Shirasaki
Takayoshi Shirasaki
LHLucinda Hensley
Lucinda Hensley
SLStanley Lemon
Stanley Lemon

2 September 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
CLChenyen Lai
Chenyen Lai
ÓÁÓscar Álvarez-García
Óscar Álvarez-García
KRKristen Read
Kristen Read
DFDon van Fossan
Don van Fossan
CCChristopher M. Conner
Christopher M. Conner
KJKurt Jarnagin
Kurt Jarnagin
The utility of Active Genetic (AG) gene conversion systems in rats and mice holds great promise for facilitating the production of complex strains harboring multiple humanizing genes. The practical application of such systems requires the identification of a robust, reusable, and highly efficient system. By characterizing twenty-eight different promoter and target site pairs we aimed to define the parameters needed to establish an efficient conversion system in male and female rats and mice. Using three specific meiosis prophase I active promoters to drive Cas9 expression. We studied several variables, including the number of Cas9 target sites, the distance between target sites, the cis versus trans configuration in linked pairs, and the effect of Cas9 copy number. In the rat, three of twelve tested configurations provided efficient AG gene conversion in the 22% - 67% range, and four others catalyzed AG in the 0.7-1% range. The rat Ddx4 (Vasa) promoter provides higher AG efficiency than the Sycp1 promoter. In mice, ten of sixteen tested configurations, using the Sycp1 and pSycp1 promoters, provided efficiency in the 0.3% - 3.2% range. In rats, Cas9 expression levels are remarkably well correlated with AG gene conversion efficiency. The rat cis r Cyp3A1 /r Cyp3A2 locus was the most successful configuration, with gene conversion efficiencies of 0.7%-67%. This target site has a special property; the two Cas9 target sites are nearly perfectly homologous in the 100 bases around the gRNA target site. Our findings identify key parameters that improve AG efficiency, including the use of two Cas9 target sites, and efficient promoters that drive high levels of Cas9 expression that are correctly timed during gamete development. These findings also uncover the unexpected benefit of high homology at paired gRNA target sites to promote efficiency. We provide new data to guide future efforts to develop yet further improved AG systems.

9 July 2010 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
SKSujoy Khan
Sujoy Khan
LDL. Davies
L. Davies
DCDale Cowley
Dale Cowley
GWG. Wild
G. Wild
WSW.A.C. Sewell
W.A.C. Sewell

17 January 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
CMCarol Milligan
Carol Milligan
DCDale Cowley
Dale Cowley
WSWilliam Stewart
William Stewart
ACAlyson Maeve Curry
Alyson Maeve Curry
EFElizabeth Forbes
Elizabeth Forbes
GHGregory Hawkins
Gregory Hawkins
Background/Objectives: Charcot first described ALS in 1869, but the specific mechanisms that mediate the disease pathology are still not clear. Intense research efforts have provided insight into unique neuroanatomical regions, specific neuronal populations and genetic associations for ALS and other neurodegenerative diseases; however, the experimental results also suggest a convergence of these events to common toxic pathways. We propose that common toxic pathways can be therapeutically targeted, and this intervention will be effective in slowing progression and improving patient quality of life. Here, we focus on understanding the role of IL6 trans-signaling in ALS disease processes. Methods: We leveraged unique mouse models of IL6 trans-signaling that we developed that recapitulate the production of active sIL6R in a genotypic and quantitative fashion observed in humans. Given that the SOD1 transgenic mouse is one of the most highly studied and characterized models of ALS, we bred SOD1G93A mice with IL6R trans-signaling mice to determine how enhanced trans-signaling influenced symptom onset and pathological processes, including neuromuscular junction (NMJ) denervation, glial activation and motoneuron (MN) survival. Results: The results indicate that in animals with enhanced trans-signaling, symptom onset and pathological processes were accelerated, suggesting a role in disease modification. Administration of an IL6R functional blocking antibody failed to alter accelerated symptom onset and disease progression. Conclusions: Future work to investigate the site-specific influence of enhanced IL6 trans-signaling and the tissue-specific bioavailability of potential therapeutics will be necessary to identify targets for precise therapeutic interventions that may limit disease progression in the 60% of ALS patients who inherit the common Il6R Asp358Ala variant.

29 August 2020 in Mammalian Genome
Verified
Journal Article
Open access
PDF file
LLLucas T. Laudermilk
Lucas T. Laudermilk
ATAdelaide Tovar
Adelaide Tovar
AHAlison K. Homstad
Alison K. Homstad
JTJoseph M. Thomas
Joseph M. Thomas
KMKathryn M. McFadden
Kathryn M. McFadden
SKSamir N. P. Kelada
Samir N. P. Kelada
Airway neutrophilia is correlated with disease severity in a number of chronic and acute pulmonary diseases, and dysregulation of neutrophil chemotaxis can lead to host tissue damage. The gene Zfp30 was previously identified as a candidate regulator of neutrophil recruitment to the lungs and secretion of CXCL1, a potent neutrophil chemokine, in a genome-wide mapping study using the Collaborative Cross. ZFP30 is a putative transcriptional repressor with a KRAB domain capable of inducing heterochromatin formation. Using a CRISPR-mediated knockout mouse model, we investigated the role that Zfp30 plays in recruitment of neutrophils to the lung using models of allergic airway disease and acute lung injury. We found that the Zfp30 null allele did not affect CXCL1 secretion or neutrophil recruitment to the lungs in response to various innate immune stimuli. Intriguingly, despite the lack of neutrophil phenotype, we found there was a significant reduction in the proportion of live Zfp30 homozygous female mutant mice produced from heterozygous matings. This deviation from the expected Mendelian ratios implicates Zfp30 in fertility or embryonic development. Overall, our results indicate that Zfp30 is an essential gene but does not influence neutrophilic inflammation in this particular knockout model.